ResMed's 10% Dividend Hike Looks Real-But RMD Still Needs a Trust Rebuild

The dividend hike supports the cash story, not yet full market confidence

ResMed's dividend increase is meaningful because it is 10% to $0.66 quarterly, and the quarter also brought record fourth-quarter revenue with full-year revenue growing 10%. That makes the update more than routine. But it is still not a full verdict on the stock.

Recent results suggest the business is holding up better than the gloomiest headlines imply. The key question now is whether that performance is enough to rebuild confidence. A higher payout can support that case, but it cannot replace it.

Q4 results show demand and cash flow remain intact

The quarter was at least in line with expectations, with Q4 revenue of $1.46 billion and non-GAAP EPS of $2.95, slightly above consensus. More important, the dividend increase appears backed by operating performance rather than financial engineering.

The core business still looks operational

ResMed finished the year with full-year revenue of $5.7 billion and FY 2026 non-GAAP diluted earnings per share of $11.17. Those figures are not consistent with a business running out of steam.

The practical sign investors should notice is repeat usage. Masks and accessories revenue rose 11%, which matters because those products reflect day-to-day customer dependence on ResMed's ecosystem. That does not settle every concern, but it does weaken the argument that demand has already broken.

The payout looks funded by cash, not stretch

ResMed also reported non-GAAP gross margin lifting to 62.3% and $1.6 billion in free cash flow in FY2026, while returning more than $1.0 billion to shareholders. That combination matters. If the dividend hike were mostly cosmetic, you would expect weaker cash generation or softer profitability.

One quarter does not prove a turnaround. Still, demand, margin, and cash all moved in a healthy range at the same time, which makes the bullish case easier to take seriously.

RMD still trades like a company rebuilding trust

The valuation story is why this quarter matters for investors. RMD is trading near the low end of its 52-week range, while MarketBeat still shows a Hold consensus rating. At the same time, the stock sits about 10% below the average of its analyst price targets. That mix suggests the market is cautious, not complacent.

What would improve the setup

The next few signals matter more than the headline dividend increase:

• Completion of the MatrixCare sale this quarter
• Continued shareholder returns after returning more than $1.0 billion to shareholders in FY2026
• Evidence that mask and accessory demand remains firm

If those boxes keep getting checked, the stock may not need a dramatic surprise to re-rate. Steadier execution and cleaner messaging could be enough.

Why the caution remains

The cautious view is straightforward: a higher dividend does not settle the larger debate. Skeptics still want proof that ResMed can keep growing, protect its market position, and sustain cash generation despite market anxiety around GLP-1 headlines.

For now, the cleanest reading is simple: ResMed's latest quarter looks solid, the dividend increase appears legitimate, and the stock still has room to move if management can keep turning steady results into restored confidence.